What are you looking for?
Start main content



The study “A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B” developed a simple scoring system to identify a patient’s likelihood to respond to a finite course of treatment with peginterferon alfa‐2a. The scoring system uses readily available demographic (age and sex) and laboratory data (ALT ratio, and HBsAg and HBV DNA levels) and could easily be incorporated into routine patient visits to help clinicians in their treatment decisions. The ability to identify patients likely to respond to peginterferon would allow clinicians to exclude nonresponders from therapy and minimize their exposure to the potential adverse effects of treatment (Aliment Pharmacol Ther. 2018 Jun 29. doi: 10.1111/apt.14862. [Epub ahead of print]).
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator, Prof Henry Chan, Director of our Centre for Liver Health. Prof Chan is an expert in antiviral treatment of chronic hepatitis and has led numerous global clinical trials in the development of antiviral therapies.
Read the full article:
More about research at CU Medicine: